Novel Cyclohexyl Amido Acid Antagonists of Lysophosphatidic Acid Type 1 Receptor for the Treatment of Pulmonary Fibrosis
- 23 January 2025
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (2) , 317-326
Abstract
Lysophosphatidic acid (LPA) is a phospholipid activating different biological functions by binding to G protein-coupled receptors (LPA1-6). Among these, the role of the LPA1 receptor in modulating fibrotic processes is well-known, making it a therapeutic target for pulmonary fibrosis and other fibrotic disorders. Herein we report the search for a new class of LPA1 antagonists for the oral treatment of idiopathic pulmonary fibrosis with a focus on hepatobiliary safety. Compound 7 excelled in in vitro and in vivo efficacy, showing significant efficacy both in PD studies and in a rodent lung fibrosis model, with a promising in vitro hepatic safety profile. However, in a dose range finding (DRF) toxicity study, compound 7 did not ensure safety regarding potential hepatobiliary toxicity, leading to its development being halted.Keywords
This publication has 34 references indexed in Scilit:
- The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world studyPulmonary Pharmacology & Therapeutics, 2024
- Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosisJournal of Lipid Research, 2023
- Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonistsToxicology and Applied Pharmacology, 2022
- Free Drug Theory – No Longer Just a Hypothesis?Pharmaceutical Research, 2022
- Drugs and hepatic transporters: A reviewPharmacological Research, 2020
- Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary FibrosisChest, 2018
- Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic SclerosisArthritis & Rheumatology, 2017
- Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1Cell, 2015
- First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptorArchives of Pharmacal Research, 2012
- Quality by Design in lead optimization: a new strategy to address productivity in drug discoveryCurrent Opinion in Pharmacology, 2011